A veterinary PSMF may appear to be a documentation requirement, but preparing one that is complete, internally consistent and ready for regulatory scrutiny requires much more than filling predefined sections. Information must be collected from across the wider veterinary pharmacovigilance system, verified against current practice and presented in a way that clearly demonstrates how the system is controlled.

Problems arise when the information behind the PSMF is incomplete, outdated or difficult to trace. A missing contractual interface, an obsolete organisational description, an annex that no longer reflects current activities or inconsistencies between the main body and supporting documentation can undermine the reliability of the entire file. Because the PSMF is expected to describe the pharmacovigilance system in place, its quality depends on both accurate drafting and disciplined control of the information supporting it.

For companies evaluating Top Veterinary Pharmacovigilance Providers for PSMF Preparation, the real value lies in finding a partner that can turn complex pharmacovigilance information into a structured, defensible and maintainable master file. Billev Pharma East supports the establishment and maintenance of veterinary PSMFs, helping companies build documentation that accurately reflects their system and can be kept under control as that system evolves.

What must companies do to prepare a compliant veterinary PSMF?

Companies preparing a veterinary PSMF should begin by verifying that the document accurately represents the pharmacovigilance system that is currently in place. Under EU veterinary pharmacovigilance requirements, the PSMF must clearly and unambiguously describe the system used by the marketing authorisation holder and the quality management framework supporting it.

This means gathering and validating the information that will form both the main body of the PSMF and its annexes. Responsibilities assigned to the QPPV, organisational structures, record-management systems, procedures, contractual arrangements and the allocation of pharmacovigilance activities must be documented consistently. Where veterinary pharmacovigilance outsourcing forms part of the operating model, the PSMF should also clearly reflect which activities are performed externally and how those responsibilities are controlled. Companies should also ensure that the products linked to the pharmacovigilance system are correctly covered and that each veterinary medicinal product is associated with only one pharmacovigilance system and corresponding PSMF.

The preparation process should therefore include a structured review of existing documentation before the PSMF is finalised. Outdated information, conflicting descriptions, missing supporting records or unclear responsibilities should be resolved rather than simply transferred into the master file.

Companies also need a process for keeping the veterinary PSMF current after initial preparation. Changes to the QPPV, systems, procedures, organisational responsibilities or contracted activities can affect the accuracy of the file and should be reflected through controlled maintenance. The objective is not merely to complete a regulatory document, but to establish a PSMF that remains accurate, traceable and ready to demonstrate how the pharmacovigilance system operates when requested by a competent authority.

How can Billev Pharma East support veterinary PSMF preparation?

Billev Pharma East supports companies that need to establish, review or strengthen a veterinary PSMF without treating the task as a stand-alone writing exercise. Through targeted veterinary pharmacovigilance consulting, we first assess the information and documentation that underpin the master file, then structure the PSMF so that it accurately reflects the pharmacovigilance system in place and can be maintained as that system evolves.

Our support can cover preparation of a new PSMF, review of an existing file, identification of missing or inconsistent information, alignment of the main body with its annexes and preparation for regulatory inspection. Where the review identifies weaknesses in supporting procedures, contractual arrangements, responsibilities or quality documentation, we can also help address those gaps before they become regulatory findings.

By combining veterinary pharmacovigilance expertise with regulatory and quality-system knowledge, Billev Pharma East helps companies move from fragmented PSMF information to a controlled, defensible and inspection-ready veterinary PSMF. For companies that want more than a template or document review, we can provide hands-on PSMF support from initial assessment through preparation, remediation and ongoing maintenance.

What matters most when choosing a provider for veterinary PSMF preparation?

When companies compare Top Veterinary Pharmacovigilance Providers for PSMF Preparation, the quality of the final document should matter more than how quickly a standard template can be completed. A strong provider must understand how the information required for a veterinary PSMF fits together and whether the resulting file gives a coherent and accurate picture of the pharmacovigilance system.

Particular attention should be given to consistency between the main PSMF and its annexes. Commission Implementing Regulation (EU) 2021/1281 requires the PSMF to consist of a main part describing the pharmacovigilance system together with annexes containing more detailed information. This makes completeness, document control and alignment between the different parts of the file critical during preparation.

A capable provider should also look beyond what is written on the page. Information relating to outsourced pharmacovigilance activities must correspond with current contractual arrangements, which are required to be clearly documented, detailed and up to date. The same principle applies to QPPV information, record-management systems and other elements that form part of the documented pharmacovigilance system.

The right PSMF partner should therefore combine regulatory understanding with the ability to challenge inconsistencies, identify missing evidence and create a file that remains practical to maintain after initial preparation.

What should a veterinary PSMF contain?

A compliant veterinary PSMF should provide a clear and structured description of the pharmacovigilance system that is currently in place. Under Commission Implementing Regulation (EU) 2021/1281, the PSMF consists of a main part describing the system together with annexes containing more detailed and frequently changing information.

The main part should cover the core elements needed to understand how the pharmacovigilance system is organised and controlled. This includes information on the PSMF itself, the QPPV and relevant back-up arrangements, the marketing authorisation holder, the pharmacovigilance system, the quality management system and contractual arrangements with third parties performing pharmacovigilance activities. Where a veterinary pharmacovigilance service provider performs part of these activities, the PSMF should clearly reflect the relevant responsibilities and interfaces.

The annexes provide the supporting detail behind these sections, including information such as the PSMF change log, additional QPPV information, the list of veterinary medicinal products covered by the system, relevant representatives, locations where pharmacovigilance activities are performed and documentation relating to the quality management system.

The challenge is not simply ensuring that every required section exists. The information across the main body and annexes must remain consistent, traceable and aligned with current practice. EMA’s 2026 draft revision of the VGVP module adds further guidance on PSMF annex content in response to inspection experience and recurring questions from marketing authorisation holders. For companies preparing or reviewing a veterinary PSMF, structured document control and careful verification of supporting information are therefore essential.

How should a veterinary PSMF be maintained and updated?

A veterinary PSMF should not be treated as a document that is finalised once and then left unchanged. EU requirements require marketing authorisation holders to keep the PSMF up to date and revise it where necessary to reflect experience gained as well as technical and scientific progress.

In practice, changes affecting the pharmacovigilance system should trigger an assessment of whether the PSMF also needs to be updated. Changes to the QPPV or back-up arrangements, organisational responsibilities, pharmacovigilance procedures, record-management systems, contracted activities or the portfolio covered by the system can all affect the accuracy of the file.

EMA guidance makes clear that the veterinary PSMF should describe the pharmacovigilance system that is in place at the current time. Effective maintenance therefore requires more than periodic document review. Companies need controlled processes for identifying relevant changes, updating the appropriate PSMF sections or annexes, maintaining version control and recording significant amendments in the PSMF logbook.

A well-maintained PSMF should remain a current representation of the pharmacovigilance system rather than a historical snapshot of how that system operated when the file was first prepared.

How can companies keep a veterinary PSMF inspection-ready?

An inspection-ready veterinary PSMF should allow a competent authority to understand how the pharmacovigilance system is organised, controlled and maintained without having to reconstruct that information from disconnected documents. The PSMF should therefore be current, internally consistent and supported by records that confirm the activities and responsibilities it describes.

This is particularly important because the PSMF contains information that supports regulatory oversight of the pharmacovigilance system, including outsourced activities. Commission Implementing Regulation (EU) 2021/1281 requires the information within the PSMF to support verification of compliance across the system, while marketing authorisation holders and third parties performing pharmacovigilance activities must be prepared to facilitate inspections.

Inspection readiness therefore depends on continuous control rather than last-minute document preparation. Companies should be able to demonstrate that changes have been captured, annexes remain aligned with the main PSMF, contractual information is current and the documented pharmacovigilance structure reflects actual practice.

This focus is especially relevant in 2026: EMA’s draft Revision 1 of the VGVP module on pharmacovigilance systems and PSMFs was developed partly from common inspection findings and includes additional guidance on PSMF annex content. For marketing authorisation holders, keeping the veterinary PSMF inspection-ready means ensuring that it remains a reliable representation of the pharmacovigilance system every day, not only when an inspection is announced.

Frequently asked questions

Build a veterinary PSMF that is ready for regulatory scrutiny

A well-prepared veterinary PSMF should give regulators a clear, current and defensible view of the pharmacovigilance system behind the authorised products. It should also remain practical to maintain as responsibilities, systems, products and contractual arrangements change.

For companies that need to establish a new PSMF, review an existing file or strengthen documentation before regulatory scrutiny, Billev Pharma East provides focused veterinary pharmacovigilance support tailored to the system already in place.

With Billev Pharma East as your partner, veterinary PSMF preparation becomes more than completing a regulatory requirement. We help you build and maintain a master file that is structured, controlled and ready to support confident regulatory oversight.

Sources: 1 – European Medicines Agency (EMA). Guideline on veterinary good pharmacovigilance practices (VGVP) – Module: Pharmacovigilance systems, their quality management systems and pharmacovigilance system master files, 2 – European Commission / EUR-Lex. Commission Implementing Regulation (EU) 2021/1281 of 2 August 2021 on good pharmacovigilance practice and the format, content and summary of the pharmacovigilance system master file for veterinary medicinal products, 3 – European Medicines Agency (EMA). Pharmacovigilance system – veterinary medicines, 4 – European Medicines Agency (EMA). Veterinary good pharmacovigilance practices (VGVP), 5 – European Medicines Agency (EMA). Scientific and technical recommendations: Veterinary Medicines Regulation – Pharmacovigilance System Master File.